Regulatory Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Big Molecule WatchOn May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Big Molecule Watch On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SCOTUS backs generic firm Hikma in skinny label disputeNext: Pfizer signs licence agreement with Chai for AI drug discovery Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
